Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy
Open Access
- 1 July 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in ClinicoEconomics and Outcomes Research
- Vol. ume 13, 629-635
- https://doi.org/10.2147/ceor.s314111
Abstract
Purpose: To analyse the healthcare resource consumption and related costs for the Italian National Health System of patients estimated to be affected by treatment-resistant depression (TRD) in Italy. Patients and Methods: This was an observational retrospective study based on administrative databases, including those related to residential/semiresidential structures, of Veneto Region and the Local Health Unit of Bergamo in Italy (for a total of around 6 million health-assisted subjects). Between July 2011 and December 2017, all adult patients with a third antidepressant (AD) after ≥ 2 AD (each one with at least ≥ 4 weeks duration, ≥ 1 prescription at maximum dosage reported in datasheets, a grace period ≤ 30 days when switching AD and treatment maintained ≥ 9 months) were included. Overall and psychiatry-related healthcare resources consumption and related costs were estimated on a 12-months based analysis. Data were re-proportioned to the Italian population. Results: We have previously estimated a total of 101,455 patients with TRD in Italy (130,049 considering the mean maximum dosage of AD). Of them, 44.2% had at least a psychiatric hospitalization/visit or accessed a residential/semiresidential structure, and 31% added another AD or a mood stabilizer/antipsychotic drug. Patients with at least one psychiatry-related hospitalization increased over the number of antidepressant lines from 12.0% during first line up to 24.5% during fourth line. Direct healthcare costs increased from € 4,405 for first line to € 9,251 from fifth line onwards. Psychiatry-related costs went from € 1,817 (first line) to € 4,606 (fifth line onwards) and were mainly driven by residential/semiresidential structures and hospitalizations. Conclusion: An upward trend with number of AD lines was observed for all healthcare resource utilization and consequently for all direct costs, thus indicating an increasing burden for patients as they move forward AD lines.Keywords
This publication has 12 references indexed in Scilit:
- Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorderCurrent Medical Research and Opinion, 2021
- A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patientsPLOS ONE, 2020
- Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine’s fast-acting antidepressant mechanismsTherapeutic Advances in Psychopharmacology, 2020
- Assessment of Patients Affected by Treatment-Resistant Depression: Findings from a Real-World Study in ItalyJournal of Psychiatry and Psychiatric Disorders, 2020
- The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional studyBMC Psychiatry, 2019
- Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant DepressionBritish Journal of Psychology, 2018
- Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristicsDepression and Anxiety, 2017
- A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant DepressionDepression Research and Treatment, 2017
- Depressione resistente al trattamento: stato dell’arte Parte II. Trattamento2015
- Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorderCurrent Medical Research and Opinion, 2010